ORAL LACOSAMIDE AND ORAL TOPIRAMATE IN PREVENTING MIGRAINE ATTACKS

COMPARISON OF EFFICACY OF ORAL LACOSAMIDE VERSUS ORAL TOPIRAMATE IN YOUNG ADULTS WITH CHRONIC MIGRAINE

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230809059091N1

Enrollment

250

Registered

2023-08-09

Start date

2023-08-09

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic migraine. Migraine

Interventions

Intervention 1: Intervention group: Group L (Oral Lacosamide). Intervention 2: Intervention group: Group T (Oral Topiramate).

Eligibility

Sex/Gender

All

Age

18 Years to 30 Years

Inclusion criteria

Inclusion criteria: ALL PATIENTS AGED 18-30 YEARS DIAGNOSED WITH MIGRAINE ACCORDING TO THE ICHD 3 CRITERIA PATIENTS WITH CHRONIC MIGRAINE AS HEADACHE OCCURRING ON 15 OR MORE DAYS PER MONTH FOR MORE THAN THREE MONTHS, WHERE AT LEAST 8 OF THOSE HEADACHE DAYS HAVE MIGRAINE FEATURES

Exclusion criteria

Exclusion criteria: PATIENTS WITH KNOWN HYPERTENSION, DIABETES OR ADVANCED CARDIAC OR RESPIRATORY DISEASE PATIENTS WITH ALLERGY TO EITHER LACOSAMIDE OR TOPIRAMATE PATIENTS WITH AN ACUTE EPISODE OF MIGRAINE IN THE LAST ONE WEEK

Design outcomes

Primary

Measure	Time frame
Frequency of migraine attacks and improvement in quality of life. Timepoint: Three months post-intervention. Method of measurement: Standardized Chronic headache quality of life questionnaire.	—

Countries

Pakistan

Contacts

Public ContactDr. Nabeel Tahir Butt

Combined Military Hospital Rahim Yar Khan

nabeel4allz@gmail.com+92 313 5969696

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026